Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026. On March 30, 2026, Merck & ...
Nasdaq

Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV. Data ...
Nasdaq

MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals

Merck MRK announced positive topline data from two pivotal phase III studies evaluating the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in ...
Benzinga.com

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study

On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...

Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study

Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in now. On March 29, Merck & Co., Inc. (NYSE: MRK) ...
Seeking Alpha

Merck Phase 3 study of Winrevair in PAH meets primary endpoint

Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study, called ...